| Editor's Note: Fierce Life Sci’s weekly digest will not publish next week, in observance of the U.S. Thanksgiving holiday. We’ll be back in your inboxes December 6. |
|
Tuesday, December 3, 2024 | 2pm ET / 11am PT Pharma companies are facing a growing challenge: delivering the right message to the right patients at the right time amid a crowded media landscape. Join us to explore holistic, patient-centered strategies that embrace diverse patient needs, driving more timely treatments and maximizing the impact of marketing efforts. Register now. 
|
|
| By Andrea Park Despite lingering barriers to equity, women continue to do incredible, groundbreaking work throughout pharma, biotech and medtech. As seen in the following profiles of 10 of the fiercest women in life sciences, they’re spearheading Big Pharma business development, guiding up-and-coming biotechs and leading clinical research into potentially lifesaving technologies and therapeutics. |
|
|
|
By Eric Sagonowsky The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. |
By Gabrielle Masson Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino-effect of leadership changes. |
By Angus Liu CSL Behring is shutting down its U.S. R&D hub for cell and gene therapy in Pasadena, California, Fierce Biotech has learned. |
|
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
By Kevin Dunleavy Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets. |
By Zoey Becker President-elect Donald Trump's choice for HHS secretary could pose risk to vaccine makers' top lines, as evidenced by sinking share prices after the appointment. |
By Nick Paul Taylor Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer and said it is analyzing the proposal before deciding on the next steps. |
By Darren Incorvaia French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma. The company’s tetraspecific antibody controlled tumors and improved survival in mice and reduced cancerous B cells in cynomolgus macaques. |
By Ben Adams The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Lilly’s Omvoh is rapidly growing into the established UC market as this IL-23 inhibitor class of drugs look to make its mark. |
By Conor Hale Medtronic has reported revenue gains across several of its medical device franchises, leading the company to nudge up its financial guidance for the remainder of the year. |
By Joseph Keenan Unexo Life Sciences, an Indian drugmaker that manufactures a medicated patch for pain relief, has been hit with a warning letter from the FDA. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we explore the rise of voice phishing, or vishing, where cybercriminals use AI to mimic voices and breach sensitive healthcare data. |
|
|---|
|
|
|
Wednesday, December 4, 2024 | 11am ET / 8am PT
Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now. 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. Sponsored by: BioCare |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Direct-To-Patient Cash Solutions for Pharma Manufacturers – learn how to leverage cash models strategically to mitigate access challenges and overcome the hurdles faced in today’s retail pharmacy environment. Sponsored by: KnippeRx |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
.png)
